Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

NCT04387500 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Renal Cell
Fumarate Hydratase Deficiency
Immunotherapy

Interventions

DRUG: Sintilimab injection plus Inlyta treatment

Sponsor

West China Hospital